Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen
- PMID: 20047017
- PMCID: PMC2678849
- DOI: 10.2174/1874471010902010009
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen
Abstract
Better tumor markers are needed for early diagnosis and staging of prostate cancer, and for monitoring therapeutic response than the currently used prostate specific antigen (PSA). Prostate specific membrane antigen (PSMA) is highly expressed on the surface of prostatic epithelial cells making it a good target for prostate cancer. In this study, mAb 3C6, specific for the extracellular epitope of PSMA, was evaluated both in vitro and in vivo for PSMA-targeting. Immunoreactivity and specificity of mAb 3C6 was evaluated by flow cytometry using prostate cell lines expressing PSMA such as LNCaP and 22Rv1 and a cell line, DU145, that expresses very little PSMA. 3C6 was conjugated with the acyclic CHX-A" DTPA chelate, radiolabeled with (111)In, and its in vitro and in vivo properties were assessed. The biodistribution of the radioimmunoconjugate evaluated in athymic mice bearing xenografts of three human prostate carcinoma cell lines shows high uptake after 72 hr in LNCaP tumors (%ID/g 22.93 +/- 6.32) and 22Rv1 (%ID/g 10.44 +/- 2.32) in contrast to low uptake by the DU145 tumors (%ID/g 4.27 +/- 0.37). Planar gamma-scintigraphic images obtained for xenografted tumor bearing mice demonstrated targeting for PSMA positive tumors suggesting possible applications in imaging and for targeted radiation therapy.
Figures





Similar articles
-
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.J Nucl Med. 2003 Apr;44(4):610-7. J Nucl Med. 2003. PMID: 12679407
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14. J Nucl Med. 2015. PMID: 25977460
-
123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid.2009 Sep 29 [updated 2009 Nov 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Sep 29 [updated 2009 Nov 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641935 Free Books & Documents. Review.
-
123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid.2009 Sep 29 [updated 2009 Nov 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Sep 29 [updated 2009 Nov 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641856 Free Books & Documents. Review.
Cited by
-
Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.Molecules. 2020 Apr 10;25(7):1743. doi: 10.3390/molecules25071743. Molecules. 2020. PMID: 32290196 Free PMC article. Review.
-
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.Br J Pharmacol. 2013 Jan;168(2):445-57. doi: 10.1111/j.1476-5381.2012.02138.x. Br J Pharmacol. 2013. PMID: 22889168 Free PMC article.
-
PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.Cancers (Basel). 2021 Aug 5;13(16):3967. doi: 10.3390/cancers13163967. Cancers (Basel). 2021. PMID: 34439121 Free PMC article. Review.
-
Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.Br J Pharmacol. 2009 Aug;157(8):1541-8. doi: 10.1111/j.1476-5381.2009.00327.x. Br J Pharmacol. 2009. PMID: 19681874 Free PMC article.
-
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.BMC Biotechnol. 2014 Sep 3;14:81. doi: 10.1186/1472-6750-14-81. BMC Biotechnol. 2014. PMID: 25186190 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43. - PubMed
-
- Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 1994;151:1283. - PubMed
-
- Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer. 1996;78:809. - PubMed
-
- Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 2004;350:2239. - PubMed
-
- Myrtle JF. Normal levels of prostate-specific antigen (PSA) In: Catalona WJ, Coffey DS, Karr JP, editors. Clinical aspects of prostate cancer: assessment of new diagnostic and management procedures. Elsevier; New York: 1989. pp. 183–189.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous